Skip to main content

SMOKING MIGHT RAISE YOUR ODDS FOR SKIN CANCER – US NEWS AND WORLD REPORT

Image result for SMOKING MIGHT RAISE YOUR ODDS FOR SKIN CANCER
Smoking may not only cause wrinkles and sagging skin, it might also increase your risk of one type of skin cancer, researchers suggest in a new report. Studies have linked smoking to a long list of health effects, including heart disease and lung cancer, but the evidence has been mixed for skin cancer. More than 3.5 million cases of the disease are found every year in the U.S., making it the most common of all cancers. While the two main forms -- basal cell carcinoma and squamous cell carcinoma -- are rarely deadly, researchers say they are on the rise. In a new study, Fiona Bath-Hextall of the University of Nottingham in England and colleagues pooled the available evidence on the link between tobacco and basal and squamous cell cancers, which start in the outer layer of the skin. Based on 14 previous studies, smokers didn't appear to have higher rates of basal cell cancer. But they did have a 52-percent increase in their risk of squamous cell cancer, based on six studies that varied in size, duration, and design. That extra risk is similar to that of ultraviolet radiation, the most well-known risk factor for squamous cell cancer, according to a commentary published along with the new results in the Archives of Dermatology. But the commentary, by Dr. Joris Verkouteren and Dr. Tamar Nijsten at Erasmus Medical Center in Rotterdam, the Netherlands, also warns that the six studies were relatively small and were not necessarily comparable. Because all of the studies are based on observations, it's impossible to say for certain whether smoking caused the increase in skin cancer risk. While current smokers had a higher risk than former smokers, there was no link between the number of cigarettes smoked per day or how long a person had been smoking.

Comments

Popular posts from this blog

HYFRECATORS AND INTERFERENCE WITH IMPLANTABLE CARDIAC DEVICES

Investigation of Hyfrecators and They are In Vitro Interference with Implantable Cardiac Devices CHRISTOPHER WEYER, DO,* RONALD J. SIEGLE, MD,†‡ AND GUILLAUME GIRARD P. ENG, EMI-EMC§ BACKGROUND Guidelines exist for minimizing potential electromagnetic interference (EMI) with electrosurgical equipment in patients with cardiac rhythm management (CRM) devices. These guidelines encompass all electrosurgical devices but are not specific for hyfrecators. OBJECTIVE To investigate the potential interference of CRM devices by hyfrecators. MATERIALS AND METHODS Using a collagen-based saline gel, three implantable pulse generators (pacemakers) and three implantable cardioverter defibrillators were tested to measure the EMI from two commonly used hyfrecators. The six devices were tested using the hyfrecator under normal use settings and on maximum power. RESULTS Hyfrecators did not interfere with defibrillators and affected pacemakers only when used in close proximity to the devi...

NEW DRUG THERAPY FOR BCC

Genentech Submits New Drug Application to FDA for Vismodegib for Rare Form of Advanced Skin Cancer Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. Vismodegib is an investigational, oral, targeted medicine designed to selectively inhibit signaling in the Hedgehog pathway, which is implicated in more than 90 percent of BCC cases. BCC is the most common type of skin cancer, which is generally considered curable by surgery. However, when it advances, BCC can cause disfiguring and debilitating effects and can ultimately be life-threatening. “We are excited by the pivotal study results that showed vismodegib substantially reduced tumor size or healed lesions for people with this rare skin cancer, which has no approved ...

TRANSACTION AND MELANOMA SURVIVAL

The rate of melanoma transaction with various biopsy techniques and the influence of tumor transaction on patient survival Mohsin Mir, MD, C. Stanley Chan, MD, Farhan Khan, MD, MBA, Bhuvaneswari Krishnan, MD, Ida Orengo, MD, and Theodore Rosen, MD Houston, Texas Background: Depth of melanoma invasion is critical because it dictates patient treatment and prognosis. Recent reports indicate melanoma transection with initial biopsy does not impact patient survival; however, tumor transaction can lead to misdiagnosis and inaccurate staging. Objective: This study assessed the rate of melanoma transaction with various biopsy techniques and the impact of tumor transaction on patient survival. Methods: We conducted a retrospective review of all melanoma cases at our institution between 2000 and 2008. Of the 490 melanoma cases identified, 479 met inclusion criteria for the study. The transaction rates of biopsy techniques were determined. Cases of transected ...